Skip to main content

Simon Schwartz Navarro

Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Cap de Secció
Bioquímica
Cross-departmental services

Simon Schwartz Navarro

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Cap de Secció
Bioquímica
Cross-departmental services

Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.

Senior research of the clinical biochemistry - drug delivery and therapy group at VHIR and Strategy director of biobanking and biomodels at Vall d'hebron Campus. President of the European Society of Nanomedicine and Executive Board member of the International Society of Nanomedicine. Former director general of the Blood and Tissue Banc of Catalonia. Former director of CIBBIM-Nanomedicine. Former scientific associate director of CIBER-BBN and coordinator of technology transfer. Former director assistance of translational research at VHIR. H-index of 48, with more that 120 high impact publications, 19 transferred patents and several EU granted projects. Co-founder of 3 biotech companies (i.e, Bsure Medical ltd). Science Advisor of the European Nanomedicine Characterization Laboratory (EU-NCL). Member of the editorial Board of Precision Nanomedicine, J. Nanotechnology and of J. of Nanotheranostics. Former editorial Board member of Eur. J. Nanomedicine and Nanomedicine-NBM. Exper member of the nanomedicine group at EMA.

Projects

ACTUALIZACIÓN DE EQUIPAMIENTOS DE ALTA TECNOLOGIA PARA LA PLATAFORMA DE IMAGEN PRECLINICA. ADQUISICION DE UN EQUIPO DE IMAGEN OPTICA

IP: Inmaculada Fuentes Camps
Collaborators: César Serrano Garcia, Santiago Ramon y Cajal Agüeras, Miquel Vila Bover, Anna Meseguer Navarro, Josep Tabernero Caturla, Joan Gavaldà Santapau, Francesc Bosch Albareda, Miguel Segura Ginard, Maria Nieves Martell Pérez-Alcalde, Victor Franco Puntes, Mª Jesús Cruz Carmona, Simon Schwartz Navarro, Eva Muñoz Couselo, Joaquim Mateo Valderrama, Juan Angel Recio Conde, Anna Rosell Novel, Josep Roma Castanyer
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 134516.7
Reference: EQC2019-006306-P
Duration: 01/01/2019 - 31/12/2020

Ministerio de Ciencia

ADQUISICIÓN DE UN MICROSCOPIO MULTIDIMENSIONAL WIDEFIELD EQUIPADO PARA REALIZAR EXPERIMENTOS IN VIVO, DESTINADO A LA PLATAFORMA DE MICROSCOPÍA DE LA UNIDAD DE ALTA TECNOLOGÍA (UAT)

IP: Inmaculada Fuentes Camps
Collaborators: Soledad Gallego Melcón, Fco Javier Santos Vicente, Gema Ariceta Iraola, Santiago Ramon y Cajal Agüeras, Marta Martínez Vicente, Anna Meseguer Navarro, Manuel Comabella Lopez, Joan Sahuquillo Barris, Miguel Segura Ginard, Simon Schwartz Navarro, Anna Rosell Novel, Meritxell Genesca Ferrer
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 177204.2
Reference: EQC2019-006309-P
Duration: 01/01/2019 - 31/12/2020

Ministerio de Ciencia

NanoDIRE-CT - Uso de nanobodies para terapia dirigida contra células madre tumorales

IP: -
Collaborators: Sandra Mancilla Zamora, NanoDIRE-CT - Uso de nanobodies para terapia dirigida contra células madre tumorales, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Simon Schwartz Navarro
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 322172.61
Reference: RTC2019-006809-1
Duration: 01/09/2020 - 31/12/2023

Ministerio de Ciencia

A Nanotechnologic Platform for the Targeted Drug and Gene Delivery Against the Advanced Cancer

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: CERCA (Centres de Recerca de Catalunya)
Funding: 9070
Reference: 2018/GINJOL/SCHWARTZ
Duration: 26/02/2018 - 18/06/2019

Related news

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Related professionals

Vanessa Segura Encinas

Vanessa Segura Encinas

Research assistant
Shock, Organ Dysfunction and Resuscitation
Read more
Olaya López  Perez

Olaya López Perez

Administration and Management
Microbiology
Read more
Juliana Silva Cardoso

Juliana Silva Cardoso

Research assistant
Pediatric Neurology
Read more
Ruperto Olivero Soldevila

Ruperto Olivero Soldevila

Research assistant
Cardiovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.